Reset
Showing 8 of 8 academic articles

CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase

Jing Yang, Pengfei Li, Pengfei Li, Pengfei Li et al. • Frontiers in Immunology (2022)

ObjectiveExtranodal natural killer/T cell lymphoma (NKTCL) is an aggressive EBV-related lymphoma, originating from NK cells or T cells. Previous study demonstrated that CD56 negative NKTCL should be recognized as a distinct subtype. In this...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2022.829366

Evaluating key predictors of breast cancer through survival: a comparison of AFT frailty models with LASSO, ridge, and elastic net regularization

Senyefia Bosson-Amedenu, Emmanuel Ayitey, Francis Ayiah-Mensah, Luyton Asare • BMC Cancer (2025)

Abstract Background Frailty models are extensively utilized in survival analysis to address unobserved heterogeneity among individuals. However, selecting the most robust model for survival prediction, especially in the context of high-dime...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12885-025-14040-z

Identification and Validation of PLOD2 as an Adverse Prognostic Biomarker for Oral Squamous Cell Carcinoma

Yawei Sun, Shuai Wang, Xingwei Zhang, Zhuhao Wu et al. • Biomolecules (2021)

Background: Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), a key enzyme that catalyzes the hydroxylation of lysine, plays a crucial role in the progression of several solid tumors. However, its spatial expression profile and pr...

DOAJ Open Access (DOAJ) DOI: 10.3390/biom11121842

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer

Xuanzhao Chen, Zeyan Li, Meihua Liang, Ziyang Zhang et al. • World Journal of Surgical Oncology (2023)

Abstract Background Triple-negative breast cancer (TNBC) is the most heterogenous and aggressive subtype of breast cancer. Chemotherapy remains the standard treatment option for patients with TNBC owing to the unavailability of acceptable t...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12957-023-03078-7

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Wei Liu, Yan Xu, Yi Wang, Lugui Qiu et al. • Journal for ImmunoTherapy of Cancer (2024)

Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or prog...

DOAJ Open Access (DOAJ) DOI: 10.1136/jitc-2023-008450

Outcomes of primary gastrointestinal diffuse large B cell lymphoma in the rituximab era

Luyao Zhang, Jianwen Zhou, Yanyan Sun, Yaodong Zhang et al. • Discover Oncology (2026)

Abstract Background Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) constitutes 30%-40% of primary extranodal lymphomas. While rituximab has significantly improved survival in nodal DLBCL, its impact on the prognosis of P...

DOAJ Open Access (DOAJ) DOI: 10.1007/s12672-026-05022-z